one digital currency, searches

Hyundai Motor: Parker will continue to be the CEO of Hyundai Motor's North American business.South Korea's exports increased by 12.4% and imports increased by 11.6% from December 1 to 10. South Korea's chip exports increased by 43% year-on-year from December 1 to 10.Trump appointed TOM BARRACK as the US ambassador to Turkey.

Haitong Securities: In 2025, the retail sales of home appliances terminals are expected to increase in volume and price. Haitong Securities reported in its research report on December 10th that the effect of the trade-in policy is remarkable. With the active actions of the central and local governments, the trade-in policy of home appliances is expected to continue in 2025. We judge that the retail sales of home appliances terminals are expected to increase in volume and price in 2025, and the domestic sales revenue of leading enterprises is expected to achieve steady growth. The average sales price of home appliances will increase significantly under the impetus of trade-in, and the profit margin of home appliance enterprises can be expected to increase. Under the downward trend of interest rates, the dividend yield of household appliances leading enterprises is still attractive. It is recommended that white and black electricity leading enterprises which have obviously benefited from the trade-in policy and have global competitiveness.Kathy Hochul, the governor of New York, said that a governor's arrest warrant would be issued to the suspect who murdered the CEO of United Health Insurance.With the general election approaching, German Chancellor Angela Scholz supports reducing the value-added tax on basic groceries. German Chancellor Angela Scholz said in an interview on the evening of December 10th local time that he was in favor of reducing the value-added tax on basic groceries from 7% to 5% to help low-income families cope with inflation. The center-left leader also said that although the opposition Conservative Party has a big lead in the polls, he is confident of winning the early election on February 23rd.

Galaxy Securities: The equity market rebounded, and the improved double-low strategy exceeded 9% during the year. According to china galaxy Securities, the last cycle (11.26-12.9) recorded 2.3%, 1.7% and 3.2% respectively (the benchmark for the same period was 2.7%). Since the beginning of this year, the performance of the three types of strategies has been 8.5%, 8.6% and 15.1% respectively (the benchmark for the same period is 6.6%), and the cumulative excess rate of return is 2-9%. In the last cycle, the equity market rebounded and repaired. Wandequan A rose by 4.05%, and CSI convertible bonds followed (2.68%), among which the double-low style (3.25%) rose higher, and the low-price enhancement and low-price large-market strategy slightly underperformed the benchmark, and the double-low improvement strategy continued to dominate.Guotai Junan's annual strategy for innovative drugs in 2025: innovative pharmaceutical companies have accelerated into the harvest period, and the valuation has been at a historical low in the past five years. Guotai Junan said that the centralized purchasing policy has become stable, mature and normalized, and the marginal impact has weakened. Innovative drugs have gained policy inclination in the medical insurance negotiation. In the past two years, the policy has continued to promote pharmaceutical innovation, and the top-level design and local supporting chain support the development of innovative drugs. Commercial insurance is expected to bring new growth momentum to China's pharmaceutical market, and the overall industry trend is upward. At present, the trend of innovative drug industry is improving, the supply continues to accelerate, and a number of domestic innovative drugs are approved soon, which is expected to drive a new round of heavy volume. At the same time, the commercialization has achieved remarkable results and has occupied a dominant position in some sub-sectors. Pharma's performance continued to differentiate, and innovative drugs and just-needed drugs performed well. Biotech commercialization continues to increase, per capita yield continues to increase, the node of turning losses is approaching, and innovation ushers in the harvest period. Horizontal comparison: compared with overseas peers, the overall valuation of domestic innovative pharmaceutical companies is in a historically low range; Vertical comparison: the valuation of SW- pharmaceutical biology and SW- chemical preparations is at a historical low in the past five years, and it is expected that the valuation of subsequent sectors will pick up.Xie Yunliang, macro chief analyst of Cinda Securities, said that historically, the establishment of a "moderately loose" policy orientation needs to meet two major conditions, namely, the domestic pressure to stabilize prices is high and the foreign Federal Reserve is in a loose cycle. At present, it is judged that both situations may exist next year.